TIDMAVO
RNS Number : 1494V
Advanced Oncotherapy PLC
26 January 2017
Advanced Oncotherapy plc
("Advanced Oncotherapy" or the "Company")
Directorate Changes
Appointment of Non-Executive Directors
Advanced Oncotherapy (AIM: AVO), the developer of
next-generation proton therapy systems for cancer treatment,
announces the appointment of Professor Steve Myers OBE and Mr Hans
von Celsing as Non-Executive Directors with immediate effect. In
addition, Mr von Celsing will become Senior Independent
Non-Executive Director. Professor Myers' appointment follows the
announcement of the Company's intention to do so, on 1 November
2016.
At the same time, Tim Lebus, Non-Executive Director, will stand
down with immediate effect.
Professor Steve Myers
Professor Myers has been part of the Advanced Oncotherapy
Leadership Team since his appointment as Executive Chairman of the
Company's fully owned subsidiary ADAM S.A., in November 2015.
Before joining Advanced Oncotherapy, Professor Myers was Head of
Medical Applications at CERN in Geneva and before that, was
Director of Accelerators and Technology at CERN. There, he was
responsible for the operation and exploitation of the whole
accelerator complex, with particular emphasis on the Large Hadron
Collider ("LHC") and the development of new projects and
technologies.
He is a Fellow of the Royal Academy of Engineering, the
Institute of Physics, the European Physical Society and
International Fellow of the American Physical Society. He is
internationally recognised for his engineering contributions and
leadership in the development of CERN's particle colliders over the
past 40 years, including the Intersecting Storage Ring Accelerator,
the Large Electron-Positron collider and the LHC.
Professor Myers has been awarded a number of international
prizes including the EPS Edison Volta Prize and the Prince of
Asturias Prize of Spain. He was awarded an OBE in 2013 for services
to science and technology. Professor Myers holds a number of
honorary degrees and advisory positions and is Chair of the
Advisory Committees of both the John Adams Accelerator Institute in
Oxford and the Cockcroft Accelerator Institute. He has published
over 300 scientific papers.
Mr Hans von Celsing
Mr von Celsing was an Adviser to Mevion Medical Systems for
eight years and supported their international expansion in Europe
and Asia. Mr von Celsing also joined Elekta, as Executive Vice
President, in its early stages in 1985. Elekta, a publicly quoted,
Swedish medical technology group, is the leading supplier of
equipment instrumentation and information systems for use in
neuroscience, cancer care and oncology management. Both Elekta and
Mevion are active in the Radiation Oncology Technology market.
Mr von Celsing has held a number of Board level roles throughout
his career, and has particular expertise in the areas of life
sciences, medical devices and diagnostics. Mr von Celsing is
currently Chairman of Clinical Laser Thermia Systems, a public
quoted medical technology company in Lund, Sweden. He is also
Chairman of Gelexir Healthcare Ltd, a medical technology company
based in Manchester, Chairman of Partner Fondkommission, an
independent investment banking company based in Gothenburg, Sweden,
and Chairman of Peptonic Medical, a publicly quoted
biopharmaceutical company in Stockholm.
Mr von Celsing's considerable experience in the growth of
radiation therapy companies and in corporate governance makes him
ideally placed to join Advanced Oncotherapy as Senior Independent
Non-Executive Director.
Commenting, Michael Sinclair, Executive Chairman of Advanced
Oncotherapy said: "Steve and Hans are hugely experienced in their
respective fields. Steve's background at CERN and his work with
accelerator technology and the medical application of this
technology have been invaluable to the business since he joined us
in 2015. Hans has a wealth of knowledge in the sector and his CV
speaks for itself in terms of his experience at Board level. We are
looking forward to having him join us and the value he will no
doubt add to the team.
"Finally, I would like to thank Tim Lebus for his immense
contribution to the Board over the last three and a half years.
Tim's experience in private equity and banking has been incredibly
helpful as the company has progressed and we are very grateful for
his guidance and we wish him well for the future."
Commenting, Hans von Celsing, said: "I am honoured to be asked
to join the Advanced Oncotherapy Board as Senior Independent
Non-Executive Director. The Company's technology is truly amazing
and promises to shape the next generation of radiation therapy
equipment. What really impresses me is the quality of the team, the
deep technical knowledge they have and the Company's collaboration
with CERN, the preeminent particle physics institute. The
foundation is there for a great commercial success story in the
medical technology field."
Information to be disclosed under Schedule 2(g) and Rule 17 of
the AIM rules
Professor Steve Myers (aged 70), currently owns 50,569 shares in
Advanced Oncotherapy
Current Directorships Directorships in the last
five years
---------------------- -----------------------------
ADAM S.A. European Organisation
for Nuclear Research (CERN)
Mr Hans Henrik von Celsing (aged 66)
Current Directorships Directorships in the last
five years
----------------------- --------------------------
Clinical Laser Thermia Sonowand A/S
Systems AB
Gelexir Healthcare Ltd BiOxyDyn Ltd
Partner Fondkommission
Peptonic Medical Ltd
Mr von Celsing holds no ordinary shares of the Company and holds
share options over 200,000 ordinary shares at an exercise price of
250p.
Other than the information contained in this announcement, there
is no further information required to be disclosed under Rule 17
and Schedule Two, paragraph (g) of the AIM Rules.
For further information, please contact:
Advanced Oncotherapy plc www.avoplc.com
Nicolas Serandour, Chief Tel: +44 20 3617 8728
Executive Officer
Michael Sinclair, Executive
Chairman
Stockdale Securities (Nomad Tel: +44 20 7601 6100
& Joint Broker)
Antonio Bossi / David Coaten
Stifel Nicolaus Europe (Joint Tel: +44 20 7710 7600
Broker)
Jonathan Senior / Ben Maddison
Walbrook PR (Financial PR Tel: +44 20 7933 8780
& IR) or avo@walbrookpr.com
Paul McManus Mob: +44 7980 541 893
Anna Dunphy Mob: +44 7876 741 001
About Advanced Oncotherapy plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with
protons that harnesses the best in modern technology. Advanced
Oncotherapy's team "ADAM", based in Geneva, focuses on the
development of a proprietary proton accelerator called Linac Image
Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the
energy levels achieved in legacy machines but in a unit that is a
quarter of the size and between a quarter and a fifth of the cost.
This compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control which is not
achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with an innovative
technology as well as better health outcomes and lower treatment
related side effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAEAAFSAENXEAF
(END) Dow Jones Newswires
January 26, 2017 02:01 ET (07:01 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2024 to May 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From May 2023 to May 2024